Ajai Chari, MD, discusses the rationale for using combination therapy in patients with multiple myeloma.
Ajai Chari, MD, associate professor of medicine at the Mount Sinai School of Medicine, discusses the rationale for using combination therapy in patients with multiple myeloma.
Historically, Chari says that every drug in the treatment landscape has only worked for a short period of time in these patients. Because of this, the agents are combined to increase both response and duration of response, while also decreasing resistance.
Lachowiez Considers the Use of Tagraxofusp in BPDCN as Bridge to SCT With Peers
March 21st 2024During a Targeted Oncology™ Case-Based Roundtable™ event, Curtis Lachowiez, MD, discussed targeted therapy for blastic plasmacytoid dendritic cell neoplasm and its role in patients who could receive allogeneic stem cell transplant.
Read More
Phase 2 and 3 Transplant-Eligible NDMM Data Build Evidence for Quadruplet Therapy
March 20th 2024During a Case-Based Roundtable® event, Laahn Foster, MD, discussed the GRIFFIN, MASTER, and PERSEUS trials in transplant-eligible newly diagnosed multiple myeloma in the first article of a 2-part series.
Read More